Can a switch to guselkumab clear stubborn psoriasis?

NCT ID NCT07746583

Recruiting now Disease control Sponsor: Janssen-Cilag Kft. Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This study looks at how well guselkumab works for people with moderate to severe psoriasis who switch from ustekinumab (or its biosimilar) in a real-world setting. Researchers will track skin clearance using the PASI score at various time points over a year. The goal is to see if the switch helps reduce psoriasis severity and is safe in routine clinical care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Guselkumab (a biologic drug) given after switching from ustekinumab
What this could lead to: If successful, this could help doctors understand whether switching to guselkumab is a safe and effective option for people with moderate to severe psoriasis in everyday practice.
What could go wrong: This is an observational study, so it cannot prove cause and effect. Results may be influenced by patient differences, and the study is relatively small.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIASIS

Contacts and locations

Locations

Semmelweis University
RECRUITING

Budapest, 1088, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.